Novo Nordisk Ups Outlook Amid Surging Demand For Weight Loss Drug Wegovy, Ozempic
Portfolio Pulse from Benzinga Neuro
Novo Nordisk (NYSE:NVO) has revised its full-year sales and operating profit outlook for 2023 due to a surge in demand for its weight-loss drug Wegovy and diabetes medication Ozempic. The company now expects sales growth of 32% to 38% and operating profit growth of 40% to 46%. The updated forecast reflects higher expectations for Ozempic sales in the U.S. and adjustments for Ozempic and Wegovy sales in the U.S.
October 14, 2023 | 4:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novo Nordisk's revised outlook due to increased demand for its drugs Wegovy and Ozempic is likely to positively impact its stock price.
The surge in demand for Novo Nordisk's drugs Wegovy and Ozempic has led the company to revise its sales and profit outlook upwards. This positive news is likely to increase investor confidence and drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100